Humans have consumed psychedelics for at least the last 10,000 years. The outlawing of psychedelics in most of the world in the 20th century didn’t stop that, but it did put an end to promising research into their psychotherapeutic applications to treat depression, addiction, PTSD, anxiety, and trauma.
Today, we’re in the midst of a psychedelic renaissance, with some psychedelics fast on their way to becoming legal medicines. One of the key players behind this movement is Rick Doblin, Ph.D.. In 01986, he founded the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit research and educational organization that has developed the medical and legal framework for the use of psychedelics to treat mental health conditions. MAPS has distributed over $20 million to fund psychedelic research and education, and in 02017 won fast-tracked “Breakthrough Therapy” designation from the FDA for using MDMA-assisted psychotherapy to treat Post-traumatic stress disorder (PTSD). With legalization now in sight, what is the future of psychedelic medicine?
Upcoming Talks
Long Now Talks are made possible through the generous support of our lead sponsor Anthropic,the Long Now Board of Directors, key supporters Ken & Maddy Dychtwald, Garrett Gruener & Amy Slater, The Jackson Square Partners Foundation,Greg Stikeleather, and Lawrence Wilkinson, and our members and supporters worldwide.
Learn more about how to foster long-term thinking with us